PortfoliosLab logo
BIB vs. LABU
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between BIB and LABU is 0.58, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.0
Correlation: 0.6

Performance

BIB vs. LABU - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ProShares Ultra Nasdaq Biotechnology (BIB) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). The values are adjusted to include any dividend payments, if applicable.

-100.00%-80.00%-60.00%-40.00%-20.00%NovemberDecember2025FebruaryMarchApril
-48.73%
-98.21%
BIB
LABU

Key characteristics

Sharpe Ratio

BIB:

-0.24

LABU:

-0.50

Sortino Ratio

BIB:

-0.06

LABU:

-0.31

Omega Ratio

BIB:

0.99

LABU:

0.96

Calmar Ratio

BIB:

-0.15

LABU:

-0.40

Martin Ratio

BIB:

-0.60

LABU:

-1.30

Ulcer Index

BIB:

16.54%

LABU:

30.75%

Daily Std Dev

BIB:

41.50%

LABU:

80.70%

Max Drawdown

BIB:

-67.24%

LABU:

-99.18%

Current Drawdown

BIB:

-59.23%

LABU:

-98.80%

Returns By Period

In the year-to-date period, BIB achieves a -11.72% return, which is significantly higher than LABU's -38.77% return.


BIB

YTD

-11.72%

1M

-12.51%

6M

-27.13%

1Y

-8.63%

5Y*

-6.61%

10Y*

-5.44%

LABU

YTD

-38.77%

1M

-23.55%

6M

-54.26%

1Y

-36.95%

5Y*

-42.36%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


BIB vs. LABU - Expense Ratio Comparison

BIB has a 0.95% expense ratio, which is lower than LABU's 1.12% expense ratio.


Expense ratio chart for LABU: current value is 1.12%, compared with the broader market range of 0.00% to 2.12%.0.50%1.00%1.50%2.00%
LABU: 1.12%
Expense ratio chart for BIB: current value is 0.95%, compared with the broader market range of 0.00% to 2.12%.0.50%1.00%1.50%2.00%
BIB: 0.95%

Risk-Adjusted Performance

BIB vs. LABU — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BIB
The Risk-Adjusted Performance Rank of BIB is 1313
Overall Rank
The Sharpe Ratio Rank of BIB is 1111
Sharpe Ratio Rank
The Sortino Ratio Rank of BIB is 1414
Sortino Ratio Rank
The Omega Ratio Rank of BIB is 1414
Omega Ratio Rank
The Calmar Ratio Rank of BIB is 1212
Calmar Ratio Rank
The Martin Ratio Rank of BIB is 1111
Martin Ratio Rank

LABU
The Risk-Adjusted Performance Rank of LABU is 66
Overall Rank
The Sharpe Ratio Rank of LABU is 55
Sharpe Ratio Rank
The Sortino Ratio Rank of LABU is 88
Sortino Ratio Rank
The Omega Ratio Rank of LABU is 99
Omega Ratio Rank
The Calmar Ratio Rank of LABU is 44
Calmar Ratio Rank
The Martin Ratio Rank of LABU is 33
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

BIB vs. LABU - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for BIB, currently valued at -0.24, compared to the broader market-1.000.001.002.003.004.00
BIB: -0.24
LABU: -0.50
The chart of Sortino ratio for BIB, currently valued at -0.06, compared to the broader market-2.000.002.004.006.008.00
BIB: -0.06
LABU: -0.31
The chart of Omega ratio for BIB, currently valued at 0.99, compared to the broader market0.501.001.502.002.50
BIB: 0.99
LABU: 0.96
The chart of Calmar ratio for BIB, currently valued at -0.15, compared to the broader market0.002.004.006.008.0010.0012.00
BIB: -0.15
LABU: -0.40
The chart of Martin ratio for BIB, currently valued at -0.60, compared to the broader market0.0020.0040.0060.00
BIB: -0.60
LABU: -1.30

The current BIB Sharpe Ratio is -0.24, which is higher than the LABU Sharpe Ratio of -0.50. The chart below compares the historical Sharpe Ratios of BIB and LABU, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.502.002.50NovemberDecember2025FebruaryMarchApril
-0.24
-0.50
BIB
LABU

Dividends

BIB vs. LABU - Dividend Comparison

BIB's dividend yield for the trailing twelve months is around 2.12%, more than LABU's 0.47% yield.


TTM20242023202220212020201920182017
BIB
ProShares Ultra Nasdaq Biotechnology
2.12%1.69%0.07%0.03%0.00%0.00%0.00%0.00%0.00%
LABU
Direxion Daily S&P Biotech Bull 3x Shares
0.47%0.35%0.35%0.00%0.00%0.00%0.28%0.64%0.17%

Drawdowns

BIB vs. LABU - Drawdown Comparison

The maximum BIB drawdown since its inception was -67.24%, smaller than the maximum LABU drawdown of -99.18%. Use the drawdown chart below to compare losses from any high point for BIB and LABU. For additional features, visit the drawdowns tool.


-100.00%-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%NovemberDecember2025FebruaryMarchApril
-59.23%
-98.80%
BIB
LABU

Volatility

BIB vs. LABU - Volatility Comparison

The current volatility for ProShares Ultra Nasdaq Biotechnology (BIB) is 24.42%, while Direxion Daily S&P Biotech Bull 3x Shares (LABU) has a volatility of 45.40%. This indicates that BIB experiences smaller price fluctuations and is considered to be less risky than LABU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%NovemberDecember2025FebruaryMarchApril
24.42%
45.40%
BIB
LABU